{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:31:57Z","timestamp":1792420317137,"version":"4.5.0"},"reference-count":113,"publisher":"Oxford University Press (OUP)","issue":"Supplement_3","license":[{"start":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T00:00:00Z","timestamp":1562803200000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The high burden and growing prevalence of invasive fungal infections (IFIs), the toxicity and interactions associated with current antifungal drugs, as well as the increasing resistance, ask for the development of new antifungal drugs, preferably with a novel mode of action. Also, the availability of oral or once-weekly alternatives would enable ambulatory treatment resulting in an improved patient's comfort and therapy adherence. However, only one new azole and two new posaconazole-formulations were marketed over the last decade. This review focuses on the antifungal drugs in the pipeline undergoing clinical evaluation. First, the newest azole, isavuconazole, with its improved safety profile and reduction in DDIs, will be discussed. Moreover, there are two glucan synthase inhibitors (GSIs) in the antifungal pipeline: rezafungin (CD101), a long-acting echinocandin with an improved stability that enables once weekly administration, and SCY-078, an orally available GSI with efficacy against azole- and echinocandin resistant isolates. A new oral formulation of amphotericin B will also be presented. Moreover, the first representative of a new antifungal class, the orotomides, with a broad spectrum and no cross-resistance with current antifungal classes, will be discussed. Finally, an overview of other antifungals that are still in earlier clinical development phases, is provided.<\/jats:p>","DOI":"10.1093\/mmy\/myz012","type":"journal-article","created":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T12:59:00Z","timestamp":1550494740000},"page":"S328-S343","source":"Crossref","is-referenced-by-count":205,"title":["Antifungal drugs: What brings the future?"],"prefix":"10.1093","volume":"57","author":[{"given":"Ruth","family":"Van Daele","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium"},{"name":"Pharmacy Department, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Spriet","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium"},{"name":"Pharmacy Department, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Wauters","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium"},{"name":"Medical Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Maertens","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium"},{"name":"Department of Hematology, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toine","family":"Mercier","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium"},{"name":"Department of Hematology, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Van Hecke","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Br\u00fcggemann","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,10]]},"reference":[{"key":"2019071100461538000_bib1","doi-asserted-by":"crossref","first-page":"165rv113","DOI":"10.1126\/scitranslmed.3004404","article-title":"Hidden killers: human fungal infections","volume":"4","author":"Brown","year":"2012","journal-title":"Sci Transl Med"},{"key":"2019071100461538000_bib2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1086\/504490","article-title":"Invasive fungal pathogens: current epidemiological trends","volume":"43","author":"Pfaller","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2019071100461538000_bib3","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrd.2017.46","article-title":"The antifungal pipeline: a reality check","volume":"16","author":"Perfect","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2019071100461538000_bib4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ijantimicag.2017.09.002","article-title":"The antifungal arsenal: alternative drugs and future targets","volume":"51","author":"Wiederhold","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2019071100461538000_bib5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/MD.0b013e3181e9441b","article-title":"Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis","volume":"89","author":"Safdar","year":"2010","journal-title":"Medicine (Baltimore)"},{"key":"2019071100461538000_bib6","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B formulations: a comparative review of efficacy and toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs"},{"key":"2019071100461538000_bib7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ccm.2017.04.003","article-title":"Overview of Treatment Approaches for Fungal Infections","volume":"38","author":"Carmona","year":"2017","journal-title":"Clin Chest Med"},{"key":"2019071100461538000_bib8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2147\/IDR.S124918","article-title":"Antifungal resistance: current trends and future strategies to combat","volume":"10","author":"Wiederhold","year":"2017","journal-title":"Infect Drug Resist"},{"key":"2019071100461538000_bib9","article-title":"Pharmacology of azoles","volume-title":"UpToDate","author":"Ashley","year":"2018"},{"key":"2019071100461538000_bib10","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/imj.13404","article-title":"Life-threatening drug interactions: what the physician needs to know","volume":"47","author":"Day","year":"2017","journal-title":"Intern Med J"},{"key":"2019071100461538000_bib11","first-page":"391","article-title":"The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects","volume":"76","author":"Lynch","year":"2007","journal-title":"Am Fam Physician"},{"key":"2019071100461538000_bib12","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00134-008-1383-2","article-title":"Mini-series: II. clinical aspects. clinically relevant CYP450-mediated drug interactions in the ICU","volume":"35","author":"Spriet","year":"2009","journal-title":"Intensive Care Med"},{"key":"2019071100461538000_bib13","volume-title":"Antimicrobial resistance: global report on surveillance","author":"World Health Organization (WHO)","year":"2014"},{"key":"2019071100461538000_bib14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/1469-0691.12513","article-title":"Update on antifungal resistance in Aspergillus and Candida","volume":"20","author":"Arendrup","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2019071100461538000_bib15","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1128\/JCM.06112-11","article-title":"Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata","volume":"50","author":"Pfaller","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2019071100461538000_bib16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/cid\/ciw691","article-title":"Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses","volume":"64","author":"Lockhart","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2019071100461538000_bib17","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3201\/eid2302.161320","article-title":"Biofilm-forming capability of highly virulent, multidrug-resistant Candida auris","volume":"23","author":"Sherry","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"2019071100461538000_bib18","first-page":"1050","article-title":"In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi","volume":"56","author":"Biswas","year":"2018","journal-title":"Med Mycol"},{"key":"2019071100461538000_bib19","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s40265-017-0805-2","article-title":"Drugs in clinical development for fungal infections","volume":"77","author":"Gonzalez-Lara","year":"2017","journal-title":"Drugs"},{"key":"2019071100461538000_bib20","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1021\/acs.jmedchem.5b00361","article-title":"Pan assay interference compounds (PAINS) and other promiscuous compounds in antifungal research","volume":"59","author":"Pouliot","year":"2016","journal-title":"J Med Chem"},{"key":"2019071100461538000_bib21","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1128\/AAC.02819-15","article-title":"Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus and other filamentous fungi","volume":"60","author":"Desai","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071100461538000_bib22","article-title":"Summary of product characteristics cresemba","author":"Pfizer"},{"key":"2019071100461538000_bib23","author":"PubChem. Isavuconazole"},{"key":"2019071100461538000_bib24","article-title":"Isavuconazole (isavuconazonium sulfate): Drug information","author":"UpToDate"},{"key":"2019071100461538000_bib25","doi-asserted-by":"crossref","first-page":"572","DOI":"10.5414\/CP202434","article-title":"Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH","volume":"54","author":"Schmitt-Hoffmann","year":"2016","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2019071100461538000_bib26","doi-asserted-by":"crossref","first-page":"e00101","DOI":"10.1128\/AAC.00101-17","article-title":"Impact of mucositis on absorption and systemic drug exposure of isavuconazole","volume":"61","author":"Kovanda","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071100461538000_bib27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/cpdd.376","article-title":"Two phase 1, open-label, mass balance studies to determine the pharmacokinetics of (14) C-labeled isavuconazonium sulfate in healthy male volunteers","volume":"7","author":"Townsend","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2019071100461538000_bib28","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cpdd.285","article-title":"Pharmacokinetic evaluation of CYP3A4-mediated drug-drug interactions of isavuconazole with rifampin, ketoconazole, midazolam, and ethinyl estradiol\/norethindrone in healthy adults","volume":"6","author":"Townsend","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2019071100461538000_bib29","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cpdd.283","article-title":"Pharmacokinetic and pharmacodynamic evaluation of the drug-drug interaction between isavuconazole and warfarin in healthy subjects","volume":"6","author":"Desai","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"2019071100461538000_bib30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/cpdd.281","article-title":"Pharmacokinetic effects of isavuconazole coadministration with the cytochrome P450 enzyme substrates bupropion, repaglinide, caffeine, dextromethorphan, and methadone in healthy subjects","volume":"6","author":"Yamazaki","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2019071100461538000_bib31","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/cpdd.284","article-title":"Pharmacokinetic assessment of drug-drug interactions of isavuconazole with the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults","volume":"6","author":"Groll","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2019071100461538000_bib32","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2019071100461538000_bib33","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/myc.12731","article-title":"Isavuconazole shortens the QTc interval","volume":"61","author":"Mellinghoff","year":"2018","journal-title":"Mycoses"},{"key":"2019071100461538000_bib34","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/cid\/ciw305","article-title":"Isavuconazole treatment of cryptococcosis and dimorphic mycoses","volume":"63","author":"Thompson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2019071100461538000_bib35","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/myc.12769","article-title":"Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: challenges and lessons of the VITAL trial","volume":"61","author":"Perfect","year":"2018","journal-title":"Mycoses"},{"key":"2019071100461538000_bib36","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/myc.12777","article-title":"Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species","volume":"61","author":"Marty","year":"2018","journal-title":"Mycoses"},{"key":"2019071100461538000_bib37","article-title":"Isavuconazole versus caspofungin in the treatment of candidaemia and other invasive Candida infections: the ACTIVE trial","author":"Kullberg"},{"key":"2019071100461538000_bib38","article-title":"Isavuconazole versus caspofungin in the treatment of candidemia and other invasive Candida infections: the ACTIVE trial","author":"Kullberg","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2019071100461538000_bib39","doi-asserted-by":"crossref","first-page":"e01034","DOI":"10.1128\/AAC.01034-17","article-title":"Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi","volume":"61","author":"Desai","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071100461538000_bib40","article-title":"Intra-subject variability and exposure-response relationship of isavuconazole in the phase 3 SECURE study in patients with invasive mould disease cause by Aspergillus spp. and other filamentous fungi","author":"Kaindl"},{"key":"2019071100461538000_bib41","doi-asserted-by":"crossref","first-page":"e00585","DOI":"10.1128\/AAC.00585-18","article-title":"Isavuconazole concentration in real-world practice: consistency with results from clinical trials","volume":"62","author":"Andes","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071100461538000_bib42","author":"PubChem. Rezafungin"},{"key":"2019071100461538000_bib43","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/ja.2016.89","article-title":"CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility","volume":"70","author":"Krishnan","year":"2017","journal-title":"J Antibiot (Tokyo)"},{"key":"2019071100461538000_bib44","article-title":"Single-dose pharmacokinetics of biafungin (CD101), a novel echinocandin, after subcutaneous administration in rat and monkey","author":"James"},{"key":"2019071100461538000_bib45","doi-asserted-by":"crossref","first-page":"e01541","DOI":"10.1128\/AAC.01541-16","article-title":"Structure-activity relationships of a series of echinocandins and the discovery of CD101, a highly stable and soluble echinocandin with distinctive pharmacokinetic properties","volume":"61","author":"James","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071100461538000_bib46","doi-asserted-by":"crossref","first-page":"e02603","DOI":"10.1128\/AAC.02603-17","article-title":"Population pharmacokinetic analyses for rezafungin (CD101) efficacy using phase 1 data","volume":"62","author":"Lakota","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071100461538000_bib47","doi-asserted-by":"crossref","first-page":"e00758","DOI":"10.1128\/AAC.00758-17","article-title":"Pharmacological basis of CD101 efficacy: exposure shape matters","volume":"61","author":"Lakota","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071100461538000_bib48","doi-asserted-by":"crossref","first-page":"e01627","DOI":"10.1128\/AAC.01627-16","article-title":"Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults","volume":"61","author":"Sandison","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071100461538000_bib49","doi-asserted-by":"crossref","first-page":"6872","DOI":"10.1128\/AAC.00701-16","article-title":"Preclinical evaluation of the stability, safety, and efficacy of CD101, a novel echinocandin","volume":"60","author":"Ong","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071100461538000_bib50","doi-asserted-by":"crossref","first-page":"i44","DOI":"10.1093\/jac\/dkx448","article-title":"We can do better: a fresh look at echinocandin dosing","volume":"73","author":"Bader","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2019071100461538000_bib51","doi-asserted-by":"crossref","first-page":"e01009","DOI":"10.1128\/AAC.01009-17","article-title":"Unraveling drug penetration of echinocandin antifungals at the site of infection in an intra-abdominal abscess model","volume":"61","author":"Zhao","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071100461538000_bib52","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1093\/jac\/dkw214","article-title":"Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates","volume":"71","author":"Pfaller","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2019071100461538000_bib53","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijantimicag.2017.03.028","article-title":"CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program","volume":"50","author":"Pfaller","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2019071100461538000_bib54","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.1128\/AAC.00620-16","article-title":"Characterization of in vitro resistance development to the novel echinocandin CD101 in Candida species","volume":"60","author":"Locke","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071100461538000_bib55","article-title":"Susceptibility of recent Candida auris isolates to the novel echinocandin CD101 and comparator antifungal agents","author":"Ghannoum M"},{"key":"2019071100461538000_bib56","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/jac\/dky153","article-title":"Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model","volume":"73","author":"Hager","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2019071100461538000_bib57","article-title":"Cidara Therapeutics reports positive topline results from phase 2 STRIVE trial of lead antifungal rezafungin","author":"Cidara Therapeutics","year":"2018","journal-title":"News Release"},{"key":"2019071100461538000_bib58","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1182\/blood.V128.22.3396.3396","article-title":"Efficacy of CD101, a novel echinocandin, in prevention of pneumocystis pneumonia (PCP): thwarting the biphasic life cycle of pneumocystis","volume":"128","author":"Cushion","year":"2016","journal-title":"Blood"},{"key":"2019071100461538000_bib59","doi-asserted-by":"crossref","first-page":"e01750","DOI":"10.1128\/AAC.01750-17","article-title":"CD101, a novel echinocandin, possesses potent antibiofilm activity against early and mature Candida albicans biofilms","volume":"62","author":"Chandra","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071100461538000_bib60","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1128\/AAC.02378-12","article-title":"Role of matrix beta-1,3 glucan in antifungal resistance of non-albicans Candida biofilms","volume":"57","author":"Mitchell","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071100461538000_bib61","article-title":"Cidara Therapeutics reports unfavorable results of phase 2 RADIANT trial of CD101 topical in VVC","author":"Cidara Therapeutics","year":"2017","journal-title":"News Release"},{"key":"2019071100461538000_bib62","article-title":"FDA grants QIDP and fast track designation to CD101 topical, Cidara Therapeutics's novel antifungal product candidate","author":"Cidara Therapeutics","year":"2016","journal-title":"News Release"},{"key":"2019071100461538000_bib63","article-title":"FDA grants QIDP and fast track designations to CD101 IV, Cidara Therapeutics's lead antifungal product candidate","author":"Cidara Therapeutics","year":"2015","journal-title":"News Release"},{"key":"2019071100461538000_bib64","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0723-2020(00)80062-4","article-title":"The discovery of enfumafungin, a novel antifungal compound produced by an endophytic Hormonema species biological activity and taxonomy of the producing organisms","volume":"23","author":"Pelaez","year":"2000","journal-title":"Syst Appl Microbiol"},{"key":"2019071100461538000_bib65","doi-asserted-by":"crossref","first-page":"e02068","DOI":"10.1128\/AAC.02068-16","article-title":"Preclinical pharmacokinetics and pharmacodynamic target of SCY-078, a first-in-class orally active antifungal glucan synthesis inhibitor, in murine models of disseminated candidiasis","volume":"61","author":"Wring","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071100461538000_bib66","author":"PubChem. SCY-078"},{"key":"2019071100461538000_bib67","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/jcp.1041430225","article-title":"Quantification of protein transcytosis in the human colon carcinoma cell line CaCo-2","volume":"143","author":"Heyman","year":"1990","journal-title":"J Cell Physiol"},{"key":"2019071100461538000_bib68","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1517\/17425255.4.4.395","article-title":"The Caco-2 cell monolayer: usefulness and limitations","volume":"4","author":"Sun","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2019071100461538000_bib69","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1128\/AAC.04445-14","article-title":"Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model","volume":"59","author":"Lepak","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071100461538000_bib70","doi-asserted-by":"crossref","first-page":"e01961","DOI":"10.1128\/AAC.01961-16","article-title":"SCY-078 is fungicidal against Candida species in time-kill studies","volume":"61","author":"Scorneaux","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071100461538000_bib71","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/jcph.1146","article-title":"Lack of impact by SCY-078, a first-in-class oral fungicidal glucan synthase inhibitor, on the pharmacokinetics of rosiglitazone, a substrate for CYP450 2C8, supports the low risk for clinically relevant metabolic drug-drug interactions","volume":"58","author":"Wring","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"2019071100461538000_bib72","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/cpdd.588","article-title":"Clinical pharmacokinetics and drug-drug interaction potential for coadministered SCY-078, an oral fungicidal glucan synthase inhibitor, and tacrolimus","volume":"8","author":"Wring","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2019071100461538000_bib73","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1093\/jac\/dkx010","article-title":"The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp","volume":"72","author":"Marcos-Zambrano","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2019071100461538000_bib74","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1093\/jac\/dks466","article-title":"Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST)","volume":"68","author":"Pfaller","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2019071100461538000_bib75","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1128\/AAC.01588-12","article-title":"In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods","volume":"57","author":"Pfaller","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071100461538000_bib76","doi-asserted-by":"crossref","first-page":"e00244","DOI":"10.1128\/AAC.00244-18","article-title":"Evaluation of the antifungal activity of the novel oral glucan synthase inhibitor SCY-078, singly and in combination, for the treatment of invasive aspergillosis","volume":"62","author":"Ghannoum","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071100461538000_bib77","doi-asserted-by":"crossref","first-page":"e00161","DOI":"10.1128\/AAC.00161-17","article-title":"Differential activity of the oral glucan synthase inhibitor SCY-078 against wild-type and echinocandin-resistant strains of Candida species","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071100461538000_bib78","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1128\/AAC.00234-15","article-title":"Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates","volume":"59","author":"Lamoth","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071100461538000_bib79","article-title":"SCY-078 demonstrates antifungal activity against Pneumocystis in a prophylactic murine model of Pneumocystis pneumonia","author":"Cushion"},{"key":"2019071100461538000_bib80","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1128\/AAC.02145-13","article-title":"Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida species and Aspergillus species isolates","volume":"58","author":"Jimenez-Ortigosa","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071100461538000_bib81","doi-asserted-by":"crossref","first-page":"e01102","DOI":"10.1128\/AAC.01102-17","article-title":"Antifungal activity of SCY-078 and standard antifungal agents against 178 clinical isolates of resistant and susceptible Candida species","volume":"61","author":"Schell","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071100461538000_bib82","doi-asserted-by":"crossref","first-page":"e00833","DOI":"10.1128\/AAC.00833-17","article-title":"De novo acquisition of resistance to SCY-078 in Candida glabrata involves FKS mutations that both overlap and are distinct from those conferring echinocandin resistance","volume":"61","author":"Jimenez-Ortigosa","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071100461538000_bib83","doi-asserted-by":"crossref","first-page":"e02396","DOI":"10.1128\/AAC.02396-16","article-title":"The emerging pathogen Candida auris: growth phenotype, virulence factors, activity of antifungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation","volume":"61","author":"Larkin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071100461538000_bib84","article-title":"A prospective, phase 2, multicenter, open-label, randomized, comparative study to estimate the safety, tolerability, pharmacokinetics, and efficacy of oral SCY-078\u00a0vs. standard-of-care following initial intravenous echinocandin therapy in the tTreatment of invasive candidiasis (including candidemia) in hospitalized non-neutropenic adults (Mycosis Study Group 010)","author":"Pappas"},{"key":"2019071100461538000_bib85","article-title":"A multicentre, randomized, evaluator-blinded, active-controlled study to evaluatie the safety and efficacy of oral SCY-078 in subjects with moderate to severe vulvovaginal candidiasis","author":"Helou"},{"key":"2019071100461538000_bib86","article-title":"SCYNEXIS\u2019s Oral SCY-078 receives FDA GIDP and fast track designations for the treatment of VVC and prevention of recurrent VVC","author":"Scynexis","year":"2018"},{"key":"2019071100461538000_bib87","article-title":"SCYNEXIS, Inc. receives FDA fast track and QIDP designations for intravenous formulation of SCY-078 for the treatment of patients with invasive fungal infections","author":"Scynexis","year":"2016"},{"key":"2019071100461538000_bib88","author":"PubChem. Amphotericin B"},{"key":"2019071100461538000_bib89","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1002\/jps.10173","article-title":"Pharmacokinetics and tissue distribution after intravenous administration of a single dose of amphotericin B cochleates, a new lipid-based delivery system","volume":"91","author":"Segarra","year":"2002","journal-title":"J Pharm Sci"},{"key":"2019071100461538000_bib90","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1128\/AAC.44.9.2356-2360.2000","article-title":"Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis","volume":"44","author":"Santangelo","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071100461538000_bib91","article-title":"Oral dosing of encochleated amphotericin B (CAmB): rapid drug targeting to infected tissue in mice with invasive candidiasis","author":"Mannino"},{"key":"2019071100461538000_bib92","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1128\/AAC.44.6.1463-1469.2000","article-title":"Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model","volume":"44","author":"Zarif","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071100461538000_bib93","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1128\/AAC.46.8.2704-2707.2002","article-title":"Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis","volume":"46","author":"Delmas","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071100461538000_bib94","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1590\/S0074-02762011000200022","article-title":"In vitro activity of amphotericin B cochleates against Leishmania chagasi","volume":"106","author":"Sesana","year":"2011","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"2019071100461538000_bib95","article-title":"Oral administration of amphotericin B (CAmB) in humans: a phase I study of tolerability and pharmacokinetics","author":"Biederdorf","year":"2016"},{"key":"2019071100461538000_bib96","author":"Matinas Biopharma","year":"2015"},{"key":"2019071100461538000_bib97","author":"Matinas Biopharma","year":"2015"},{"key":"2019071100461538000_bib98","author":"Matinas BioPharma","year":"2016"},{"key":"2019071100461538000_bib99","author":"PubChem. Olorofim"},{"key":"2019071100461538000_bib100","doi-asserted-by":"crossref","first-page":"12809","DOI":"10.1073\/pnas.1608304113","article-title":"F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase","volume":"113","author":"Oliver","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019071100461538000_bib101","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jgg.2015.04.004","article-title":"Pyrimidine metabolism: dynamic and versatile pathways in pathogens and cellular development","volume":"42","author":"Garavito","year":"2015","journal-title":"J Genet Genomics"},{"key":"2019071100461538000_bib102","doi-asserted-by":"crossref","first-page":"e01157","DOI":"10.1128\/mBio.01157-17","article-title":"Pharmacodynamics of the orotomides against Aspergillus fumigatus: new opportunities for treatment of multidrug-resistant fungal disease","volume":"8","author":"Hope","year":"2017","journal-title":"MBio"},{"key":"2019071100461538000_bib103","article-title":"Pharmacokinetics of the novel antifungal agent F901318 in mice, rats, and cynomolgus monkeys","author":"Law"},{"key":"2019071100461538000_bib104","article-title":"Multiple dose pharmacokinetics of an immediate-release tablet formulation of F901318 in healthy male and female subjects","author":"Kennedy"},{"key":"2019071100461538000_bib105","doi-asserted-by":"crossref","first-page":"e00231","DOI":"10.1128\/AAC.00231-18","article-title":"Effect of the novel antifungal drug F901318 (Olorofim) on the growth and viability of Aspergillus fumigatus","volume":"62","author":"du Pre","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071100461538000_bib106","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1093\/infdis\/jix479","article-title":"Pharmacodynamics of the novel antifungal agent F901318 for acute sinopulmonary aspergillosis caused by Aspergillus flavus","volume":"217","author":"Negri","year":"2018","journal-title":"J Infect Dis"},{"key":"2019071100461538000_bib107","article-title":"An open-label study in healthy volunteers to evaluate the potential for cytochrome P450 3A4 inhibition by F901318 using oral midazolam as a probe","author":"Kennedy"},{"key":"2019071100461538000_bib108","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1093\/jac\/dkx177","article-title":"In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates","volume":"72","author":"Buil","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2019071100461538000_bib109","doi-asserted-by":"crossref","first-page":"e00487","DOI":"10.1128\/AAC.00487-18","article-title":"EUCAST Determination of olorofim (F901318) susceptibility of mould species, method validation and MICs","volume":"62","author":"Jorgensen","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071100461538000_bib110","article-title":"In-vitro activity of F901318 and comparators against clinical isolates of cryptic species of Aspergillus","author":"Rivero-Men\u00e9ndez"},{"key":"2019071100461538000_bib111","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1093\/jac\/dkx065","article-title":"Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans","volume":"72","author":"Wiederhold","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2019071100461538000_bib112","article-title":"The orotomide F901318 is efficacious in a murine model of Coccidioides meningitis","author":"Wiederhold"},{"key":"2019071100461538000_bib113","article-title":"Assessment of the duration of infusion on the tolerability and repeat dose pharmacokinetics of F901318 in healthy volunteers","author":"Kennedy"}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/mmy\/article-pdf\/57\/Supplement_3\/S328\/28925753\/myz012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T01:19:41Z","timestamp":1662945581000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/57\/Supplement_3\/S328\/5530955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,1]]},"references-count":113,"journal-issue":{"issue":"Supplement_3","published-online":{"date-parts":[[2019,7,10]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myz012","relation":{},"ISSN":["1369-3786","1460-2709"],"issn-type":[{"value":"1369-3786","type":"print"},{"value":"1460-2709","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,6]]},"published":{"date-parts":[[2019,6,1]]}}}